Global Vascular Closure Devices (Vcds) Market is
anticipated to reach USD 1.3 billion by 2024, according to a new report by
Grand View Research, Inc. Growing popularity of femoral artery cardiac
catheterization and high success rate of VCDs for improved patient comfort and
shortening of hemostasis time are potential factors for the projected growth of
VCDs market over the forecast period. Adoption of VCDs for diagnostic and
therapeutic interventions that facilitate endovascular image-guided interventions
to detect coronary heart disease are expected to contribute toward the growth
of this market throughout the forecast period.
Moreover,
ability of VCDs to overcome complications, such as prolonged bed rest and
patient discomfort caused by manual compression, is expected to revolutionize
the market growth over the forecast period.
Browse
Details of Report @
https://www.grandviewresearch.com/industry-analysis/vascular-closure-device-vcd-market
Further
Key Findings from the Study Suggest:
- VCDs offer three types of products, which includes active
approximators, passive approximators, and external hemostatic devices. Out
of all three, active approximators dominated the market in 2015 as they
shorten the time to ambulation and possess high efficiency rate.
- Amongst the different end-users of VCDs, acute care facilities
accounted for the largest share and are expected to maintain their
dominant position over the forecast period. This is attributed to the
rising popularity of VCDs in acute care treatment facilities.
- Asia Pacific is estimated to witness the fastest growth over the
forecast period owing to the presence of unmet demands by the hospitals
and rising R&D investment in this region.
- Some key players operating in this industry include Cardinal
Health; Abbott Laboratories; COOK; Medtronic; W L. Gore & Associates;
Boston Scientific Corporation; Biotronik GMBH & CO.KG; TZ Medical,
Inc.; C. R. Bard, Inc.; ST. JUDE MEDICAL; Cardiva Medical, Inc.; Merit
Medical Systems, Inc.; ESSENTIAL MEDICAL, INC; and Scion BioMedical.
- This market is expected to witness lucrative growth owing to high
level of competitive rivalry, which translates to high revenue generation
in this sector. These prominent players are opting for different
strategies to boost their status in this market. Companies are involved in
developing novel VCDs and in turn broaden their product portfolios.
Acquisition and collaboration with small companies in order to enhance
presence is also expected to propel growth in this vertical.
- For instance, in October 2015, Cardinal Health acquired Johnson
& Johnson's Cordis business. Cordis is a leader in manufacturing and
marketing of cardiology and endovascular devices. This acquisition was
intended to expand Cardinal’s VCD product catalog to reinforce its status
in the market.
- North America dominated the market in 2015, with over 33% of total
revenue. The presence of key players in this region, which are primarily
involved in marketing and development of innovative VCDs, to facilitate
cardiac surgeries can be attributed to the largest share of North America.
Demand of products for monitoring of coronary artery disease is also
expected to drive growth.
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: [email protected]
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/